The high prevalence of CD (3.5%) in autoimmune cholestasis suggests that serological screening for CD should be routinely performed in such patients by immunoglobulin A endomysial or human tissue transglutaminase antibodies.
No takes yet. Share an insight, caveat, or question.
Volta et al. (2002) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: